Suppr超能文献

颅内动脉闭塞性前循环卒中患者动脉内取栓与标准静脉溶栓治疗的单中心经验

Intra-arterial thrombectomy versus standard intravenous thrombolysis in patients with anterior circulation stroke caused by intracranial arterial occlusions: a single-center experience.

机构信息

Stroke Unit, Department of Neuroscience, University of Rome Tor Vergata, Rome, Italy; Fondazione Santa Lucia IRCCS, Rome, Italy.

出版信息

J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e323-31. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.001. Epub 2013 Feb 4.

Abstract

BACKGROUND

Severely impaired patients with persisting intracranial occlusion despite standard treatment with intravenous (IV) administration of recombinant tissue plasminogen activator (rtPA) or presenting beyond the therapeutic window for IV rtPA may be candidates for interventional neurothrombectomy (NT). The safety and efficacy of NT by the Penumbra System (PS) were compared with standard IV rtPA treatment in patients with severe acute ischemic stroke (AIS) caused by large intracranial vessel occlusion in the anterior circulation.

METHODS

Consecutive AIS patients underwent a predefined treatment algorithm based on arrival time, stroke severity as measured by the National Institutes of Health Stroke Scale (NIHSS) score, and site of arterial occlusion on computed tomographic angiography (CTA). NT was performed either after a standard dose of IV rtPA (bridging therapy [BT]) or as single treatment (stand-alone NT [SAT]). Rates of recanalization, symptomatic intracranial bleeding (SIB), mortality, and functional outcome in NT patients were compared with a historical cohort of IV rtPA treated patients (i.e., controls). Three-month favourable outcome was defined as a modified Rankin Scale (mRS) score ≤2.

RESULTS

Forty-six AIS patients were treated with NT and 51 with IV rtPA. The 2 groups did not differ with regard to demographics, onset NIHSS score (18.5±4 v 17±5; P=.06), or site of intracranial occlusion. Onset-to-treatment time in the NT and IV rtPA groups was 230 minutes (±78) and 176.5 (±44) minutes, respectively (P=.001). NT patients had significantly higher percentages of major improvement (≥8 points NIHSS score change at 24 hours; 26% v 10%; P=.03) and partial/complete recanalization (93.5% v 45%; P<.0001) compared to controls. Treatment by either SAT or BT similarly improved the chance of early recanalization and early clinical improvement. No significant differences were observed in the rate of SIB (11% v 6%), 3-month mortality (24% v 25%), or favorable outcome (40% v 35%) between NT and IV rtPA patients.

CONCLUSIONS

Despite significantly delayed time of intervention, NT patients had higher rates of recanalization and early major improvement, with no differences in symptomatic intracranial hemorrhages. Early NIHSS score improvement did not translate into better 3-month mortality or outcome. NT seems a safe and effective adjuvant treatment strategy for selected patients with severe AIS secondary to large intracranial vessel occlusion in the anterior circulation.

摘要

背景

尽管接受了标准的静脉内(IV)重组组织型纤溶酶原激活剂(rtPA)治疗,但仍存在颅内持续闭塞且病情严重的患者,或在 IV rtPA 的治疗时间窗之外就诊的患者,可能是介入性神经血栓切除术(NT)的候选者。在因前循环大血管闭塞导致的严重急性缺血性卒中(AIS)患者中,比较了 Penumbra 系统(PS)的 NT 与标准 IV rtPA 治疗的安全性和疗效。

方法

连续的 AIS 患者根据到达时间、国立卫生研究院卒中量表(NIHSS)评分测量的卒中严重程度以及计算机断层血管造影(CTA)上的动脉闭塞部位,采用预先设定的治疗算法。NT 要么在标准剂量 IV rtPA 后进行(桥接治疗 [BT]),要么作为单一治疗(单独 NT [SAT])。比较 NT 患者的再通率、症状性颅内出血(SIB)、死亡率和功能结局与接受 IV rtPA 治疗的历史队列(即对照组)的患者。3 个月时的良好结局定义为改良 Rankin 量表(mRS)评分≤2。

结果

46 例 AIS 患者接受了 NT 治疗,51 例患者接受了 IV rtPA 治疗。两组在人口统计学特征、发病 NIHSS 评分(18.5±4 与 17±5;P=.06)或颅内闭塞部位方面没有差异。NT 组和 IV rtPA 组的发病至治疗时间分别为 230 分钟(±78)和 176.5 分钟(±44)(P=.001)。与对照组相比,NT 组患者 24 小时 NIHSS 评分变化≥8 分的主要改善比例(26% 比 10%;P=.03)和部分/完全再通比例(93.5% 比 45%;P<.0001)显著更高。无论是 SAT 还是 BT 治疗,早期再通和早期临床改善的机会都有所增加。NT 组和 IV rtPA 组的 SIB 发生率(11% 比 6%)、3 个月死亡率(24% 比 25%)或良好结局(40% 比 35%)均无显著差异。

结论

尽管干预时间明显延迟,但 NT 组患者的再通率和早期主要改善率更高,且症状性颅内出血无差异。早期 NIHSS 评分的改善并未转化为 3 个月死亡率或结局的改善。NT 似乎是一种安全有效的治疗策略,适用于因前循环大血管闭塞导致的严重 AIS 患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验